CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 95 enrolled
Drug / intervention
Oraquick HIV Self Test - Choice +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03271424
NCT03271424N/ACompleted
CompareCT.gov

Innovations in HIV Testing to Enhance Care for Young Women and Their Peers and Partners

University of North Carolina, Chapel Hill·interventional·Posted Sep 5, 2017·Updated Jan 19, 2018

In Brief

A clinical study evaluating Oraquick HIV Self Test - Choice, Atomo HIV Self Test - Choice, and 1 other intervention for Human Immunodeficiency Virus. Completed, enrolled 95 participants across 1 site.

Detailed Summary

The investigators propose to improve HIV prevention and care through expanding HIV testing options to include self-testing for young women, their peers and their sex partners, and by facilitating linkage to care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesSouth Africa
CollaboratorsUniversity of Witwatersrand, South Africa, University of California, San Francisco, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 5, 2017
Enrollment StartOct 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.8 years ago

Interventions

Oraquick HIV Self Test - Choiceother

This is an oral swab in home HIV test.

Atomo HIV Self Test - Choiceother

This is a blood finger prick in home HIV test.

Oraquick HIV Self Test and Atomo HIV Self Test - Bothother

This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.